drugset / Trial / NCT02550054

Summary

The main goal of this trial is to investigate whether early administration of human erythropoietin (EPO) in preterm infants improves neurodevelopmental outcome at 18 months corrected age. This study is designed as randomized, double-masked, placebo controlled multicenter study involving at least 312 patients.

Timeline

Start
2015-09-08
Primary completion
2016-12-30
Completion
2016-12-30

Outcome

Outcome not reported

Stopped: “The study was concluded as planned upon reaching its predetermined endpoint, which included the completion of data collection and achievement of the necessary sample size for statistical significance.”

Drugs

EvaluationDrugModalityDoseRoute
Subject Epo Unknown 400 iu/kg Intravenous

Indications